...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Not adding up!
Reply New Message
Prev Message Back To Forum Threaded View Next Message

So, why give it away at this price when:

1. You're at the advanced stage of development that you are with ZEN-3694?

It's a licensing deal. What about the deal is --> giving it away?

 

2. You are expecting some jaw-dropping numbers over at Resverlogix with regards to the Covid-19 trial?

Different company.  How is this relevant?

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply